Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/J&J Procrit arbitration

Executive Summary

Johnson & Johnson will retain license to sell Procrit (epoetin alfa) in the U.S. following Oct. 18 decision by an arbitration panel, but will pay Amgen $150 mil. in damages. J&J is seeking attorneys' fees. Amgen argued that J&J intentionally sold Procrit in Amgen's exclusive dialysis market, violating a 1985 agreement between the companies. Amgen sells epoetin alfa as Epogen for dialysis patients, while J&J sells Procrit in non-dialysis markets (1"The Pink Sheet" March 20, 2000, p. 19)...
Advertisement

Related Content

Amgen Effort To Reclaim Procrit Rights From J&J Moving To Trial Phase
Amgen Effort To Reclaim Procrit Rights From J&J Moving To Trial Phase
Advertisement
UsernamePublicRestriction

Register

PS040637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel